博士后合作导师

李俊东

邮    箱：lijd@sysucc.org.cn

单位及科室：中山大学肿瘤防治中心 妇科

职      务：科主任、妇科师生党支部书记

职      称：主任医师、教授

主要研究方向：卵巢癌、子宫内膜癌、子宫颈癌等常见妇科恶性肿瘤的诊治，致力于卵巢癌疑难病例的多学科综合治疗及个体化治疗、临床研究和耐药基础研究。

主持项目：

1、国家自然科学基金面上项目，81972442，EYA2促进TOP1胞浆转位抑制凋亡体形成介导卵巢癌耐药及分子机制，2020/1-2023/12，主持，在研。

2、广东省自然科学基金面上项目，2019A1515011194，EYA2抑制凋亡小体介导卵巢癌化疗耐药及其分子机制，2019/10-2022/9，主持，在研。

3、中山大学肿瘤防治中心308项目，308-2016-03-02，氟达拉滨联合多柔比星脂质体对比多柔比星脂质体单药治疗铂耐药性复发性卵巢上皮癌的前瞻、随机对照、开放性Ⅱ期临床研究，2017/2-2024/2，主持，在研。

4、国家自然科学基金面上项目，82102783，布加替尼（Brigatinib）抑制卵巢癌细胞PD-L1表达促 进免疫杀伤作用的研究，2022/1-2024/12，参与，在研。

近五年代表性成果：

  1. Wei Wei , Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang,Xin Huang,Yongwen Huang,Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu,Jundong Li. Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 2022;10(5):e004338.
  2. Qiaqia Li , Yinghong Deng , Wei Wei , Fan Yang , An Lin , Desheng Yao , Xiaofeng Zhu , Jundong Li. Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer. Front Oncol. 2022,12,23:859409.
  3. Li JB, Qiu ZY, Liu Z, Zhou Q, Feng LF, Li JD, Zhang X. Gender Differences in Factors Associated with Clinically Meaningful Weight Loss among Adults Who Were Overweight or Obese: A Population-Based Cohort Study. Obes Facts. 2021;14(1):108-120.
  4. Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun T, Wu RY, Jiao L, Li DD, Ji J, Zhang HL, Yu Y, Chen YH, Feng GK, Deng R, Li JD, Zhu XF. CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy. 2021 Dec;17(12):4323-4340.
  5. Liu G, Yan J, Long S, Liu Z, Gu H, Tu H, Li J. Is Routine Gastroscopy/Colonoscopy Reasonable in Patients With Suspected Ovarian Cancer: A Retrospective Study. Front Oncol. 2021,7,0 1.11:608999.
  6. Lan C, Shen J, Wang Y, Li J, Liu Z, He M, Cao X, Ling J, Huang J, Zheng M, Zou G, Yan H, Liu Q, Yang F, Wei W, Deng Y, Xiong Y, Huang X. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol, 2020.12.01,38(34):4095-4106.
  7. Huang X, Xie C, Tang J, He W, Yang F, Tian W, Li J, Yang Q, Shen J, Xia L, Lan C. Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial. BMC Med, 2020.10.05,18(1):267.